153 related articles for article (PubMed ID: 38578002)
21. Blood MALT1 deficiency is common and relates to unfavorable induction therapy response and survival profile in acute myeloid leukemia patients.
Geng H; Wang Y; Wang S
Hematology; 2022 Dec; 27(1):1176-1183. PubMed ID: 36314929
[TBL] [Abstract][Full Text] [Related]
22. Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study.
Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
Acta Derm Venereol; 2021 Jan; 101(1):adv00357. PubMed ID: 33320277
[TBL] [Abstract][Full Text] [Related]
23. MALT1 regulates Th2 and Th17 differentiation
Wang Q; Wang Y; Liu Q; Chu Y; Mi R; Jiang F; Zhao J; Hu K; Luo R; Feng Y; Lee H; Zhou D; Mi J; Deng R
Front Immunol; 2022; 13():913830. PubMed ID: 35967391
[TBL] [Abstract][Full Text] [Related]
24. Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Van Muijen ME; Thomas SE; Groenewoud HMM; Otero ME; Ossenkoppele PM; Njoo MD; Dodemont SRP; Kop EN; Berends MAM; Koetsier MIA; Mommers JM; Körver JEM; Tupker RA; De Bruin-Weller MS; Weppner-Parren LJMT; Peters B; Kleinpenning MM; Kuijpers ALA; Arnold WP; Van Lümig PPM; Van den Reek JMPA; De Jong EMGJ
Acta Derm Venereol; 2022 May; 102():adv00712. PubMed ID: 35356990
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.
Maul JT; Djamei V; Kolios AGA; Meier B; Czernielewski J; Jungo P; Yawalkar N; Mainetti C; Laffitte E; Spehr C; Anliker M; Streit M; Augustin M; Rustenbach S; Conrad C; Hafner J; Boehncke WH; Borradori L; Gilliet M; Itin P; French LE; Häusermann P; Navarini AA
Dermatology; 2016; 232(6):640-647. PubMed ID: 28076860
[TBL] [Abstract][Full Text] [Related]
26. Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome.
Ye Z; Chen L; Fang Y; Zhao L
J Clin Lab Anal; 2022 Jan; 36(1):e24112. PubMed ID: 34788483
[TBL] [Abstract][Full Text] [Related]
27. MALT1 in asthma children: A potential biomarker for monitoring exacerbation risk and Th1/Th2 imbalance-mediated inflammation.
Liu L; Gao Y; Si Y; Liu B; Liu X; Li G; Wang R
J Clin Lab Anal; 2022 May; 36(5):e24379. PubMed ID: 35353938
[TBL] [Abstract][Full Text] [Related]
28. Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept.
Yang A; Xin X; Yang W; Li M; Yang W; Li L; Liu X
Ann Dermatol Venereol; 2019 May; 146(5):363-371. PubMed ID: 31047699
[TBL] [Abstract][Full Text] [Related]
29. GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis.
Xia X; Cao G; Sun G; Zhu L; Tian Y; Song Y; Guo C; Wang X; Zhong J; Zhou W; Li P; Zhang H; Hao J; Li Z; Deng L; Yin Z; Gao Y
J Clin Invest; 2020 Oct; 130(10):5180-5196. PubMed ID: 32831293
[TBL] [Abstract][Full Text] [Related]
30. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
[TBL] [Abstract][Full Text] [Related]
31. Discovery of orally bioavailable inhibitors of MALT1 with in vivo activity for psoriasis.
Nunettsu Asaba K; Okimura K; Adachi Y; Tokumaru K; Goto Y; Fujii S; Watanabe A; Sakai C; Sakurada E; Amikura K; Aoki T
Bioorg Med Chem Lett; 2023 Feb; 82():129155. PubMed ID: 36720321
[TBL] [Abstract][Full Text] [Related]
32. Dual specificity phosphatase 22 relates to skin lesion degree and biologics history, while its longitudinal elevation during treatment reflects better outcome in psoriasis patients.
E C; Fang Y; Wu S; Meng Z; Qin G; Yang J
J Clin Lab Anal; 2022 Feb; 36(2):e24199. PubMed ID: 34973040
[TBL] [Abstract][Full Text] [Related]
33. Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis.
Ziolkowska-Banasik D; Hadas E; Pastuszczak M
J Drugs Dermatol; 2024 Feb; 23(2):74-77. PubMed ID: 38306130
[TBL] [Abstract][Full Text] [Related]
34. The paracaspase MALT1 in psoriasis.
Hailfinger S; Schulze-Osthoff K
Biol Chem; 2021 Nov; 402(12):1583-1589. PubMed ID: 34192836
[TBL] [Abstract][Full Text] [Related]
35. Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry.
McLean RR; Sima AP; Beaty S; Low R; Spitzer RL; Stark JL; Lesser E; Lee E; Armstrong A
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2739-2751. PubMed ID: 37755689
[TBL] [Abstract][Full Text] [Related]
36. MALT1 targeting suppresses CARD14-induced psoriatic dermatitis in mice.
Van Nuffel E; Staal J; Baudelet G; Haegman M; Driege Y; Hochepied T; Afonina IS; Beyaert R
EMBO Rep; 2020 Jul; 21(7):e49237. PubMed ID: 32343482
[TBL] [Abstract][Full Text] [Related]
37. Keratinocyte-intrinsic BCL10/MALT1 activity initiates and amplifies psoriasiform skin inflammation.
Kurgyis Z; Vornholz L; Pechloff K; Kemény LV; Wartewig T; Muschaweckh A; Joshi A; Kranen K; Hartjes L; Möckel S; Steiger K; Hameister E; Volz T; Mellett M; French LE; Biedermann T; Korn T; Ruland J
Sci Immunol; 2021 Nov; 6(65):eabi4425. PubMed ID: 34826258
[TBL] [Abstract][Full Text] [Related]
38. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
[TBL] [Abstract][Full Text] [Related]
39. Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis.
Choi S; Oh S; Yoon HS
Ann Dermatol; 2022 Jun; 34(3):173-181. PubMed ID: 35721333
[TBL] [Abstract][Full Text] [Related]
40. Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules.
He H; Wu W; Zhang Y; Zhang M; Sun N; Zhao L; Wang X
Front Pharmacol; 2021; 12():586827. PubMed ID: 34276352
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
